Background Non–small-cell lung cancer with sensitive mutations of the epidermal growth
factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as gefitinib…

Background Patients with non-small-cell lung cancer harbouring mutations in the epidermal
growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase …

Purpose Programmed death-1 (PD-1), a coinhibitory immune signal receptor expressed in T
cells, binds to PD-1 ligand and regulates antitumor immunity. Nivolumab is an anti–PD-1 …

Background Resistance to first-generation or second-generation EGFR tyrosine kinase
inhibitor (TKI) monotherapy develops in almost half of patients with EGFR-positive non-small-cell …

Induced pluripotent stem cells (iPS cells) are a promising source for a cell-based therapy to
treat Parkinson’s disease (PD), in which midbrain dopaminergic neurons progressively …

Purpose This multicenter phase II study was undertaken to investigate the efficacy and
feasibility of gefitinib for patients with advanced non–small-cell lung cancer (NSCLC) harboring …

… Ueda and Isamu Okamoto, Kinki University, Osakasayama; Hirofumi Yasui, Shizuoka Cancer
Center, Shizuoka; Tomohiro Nishina, National Hospital Organization Shikoku Cancer Center …

Via in situ intercalative free-radical polymerization, we prepared clay/poly(methyl methacrylate)
(PMMA) and clay/polystyrene (PS) nanocomposites from lipophilized smectic clays. The …

BACKGROUND: To improve the efficacy of radiofrequency ablation (RFA) for the treatment
of intermediate‐sized hepatocellular carcinomas (HCCs), the authors compared RFA …

PURPOSE Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor combined with
cytotoxic chemotherapy is highly effective for the treatment of advanced non–small-cell lung …